Back to top
more

Azenta (AZTA)

(Delayed Data from NSDQ)

$52.09 USD

52.09
357,607

-0.45 (-0.86%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $52.08 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Inspire Medical Systems (INSP) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Inspire (INSP) delivered earnings and revenue surprises of 1,325% and 0.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Outset Medical, Inc. (OM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hims & Hers Health, Inc. (HIMS) Moves 8.3% Higher: Will This Strength Last?

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Shaun Pruitt headshot

3 Stocks to Watch After Impressive Earnings Beats

by Shaun Pruitt

In a somewhat quiet earnings lineup this week, several stocks stand out after posting strong quarterly results on Monday.

Azenta (AZTA) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Brooks (AZTA) delivered earnings and revenue surprises of 533.33% and 8.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

American Well Corporation (AMWL) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

American Well Corporation (AMWL) delivered earnings and revenue surprises of -9.52% and 4.59%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 103.57% and 4.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Azenta (AZTA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Brooks (AZTA) delivered earnings and revenue surprises of -20% and 8.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 16.67% and 6.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Pfizer (PFE) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Pfizer (PFE) delivered earnings and revenue surprises of 23% and 7.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Down -23.84% in 4 Weeks, Here's Why You Should You Buy the Dip in Brooks (AZTA)

by Zacks Equity Research

Brooks (AZTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Azenta (AZTA) Beats Q1 Earnings Estimates

by Zacks Equity Research

Brooks (AZTA) delivered earnings and revenue surprises of 100% and 1.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Azenta (AZTA) Q3 Earnings Beat Estimates

by Zacks Equity Research

Brooks (AZTA) delivered earnings and revenue surprises of 50% and 0.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics, Inc. (FLGT) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 6.85% and 2.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Brooks (AZTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Azenta (AZTA) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Brooks (AZTA) delivered earnings and revenue surprises of 9.09% and 2.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1Life Healthcare, Inc. (ONEM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

1Life Healthcare, Inc. (ONEM) delivered earnings and revenue surprises of 4.08% and 2.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Brooks (AZTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Brooks (AZTA) Climb 57% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 56.7% in Brooks (AZTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Brooks (AZTA) Climb 57% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Brooks (AZTA) points to a 57.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Azenta (AZTA) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Brooks (AZTA) delivered earnings and revenue surprises of 50% and 3.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Brooks (AZTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Brooks (AZTA) Loses 7.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Brooks (AZTA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Rimmi Singhi headshot

Save Your Portfolio by Getting Rid of These 4 Toxic Stocks

by Rimmi Singhi

Investors who can spot the overpriced stocks and shun them at the right time are the ones likely to make a profit. SGRY, ASAI, BLKB and AZTA are a few toxic stocks that you should disown right away.